Thus, therapeutic utility of MEK inhibition may have broad neuroprotective properties in other neurodegenerative diseases such as AD-related dementia and Parkinson’s disease where autophagic lysosomal activity plays a role. This evidence concerns the gene MAP2K7 and Parkinson disease.